Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trial Research
BioSante Pharmaceuticals Completes $18.3 Million Private Placement of Common Stock
June 26th, 2007
BioSante Pharmaceuticals, Inc. (AMEX: BPA) announced that it has completed its previously announced $18.3 million private placement of shares of its common stock and warrants to institutional and other accredited investors. A total of 3,054,999 shares of common stock were sold at a purchase price of $6.00 per share. Investors also received warrants to purchase 763,750 shares of common stock at an exercise price of $8.00 per share. Rodman & Renshaw, LLC served as lead placement agent with Oppenheimer & Co. Inc. serving as an additional placement agent for the transaction. Approximately half of the shares were placed with U.S.-based investors and half with Israel-based investors....
Source: Drug Law Weekly (2007-06-26)
|
